Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 432-442

  Achari, Chandrani ^a   Reddy, Gorla V ^a   Reddy, T C M ^a   Reddanna, Pallu ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

Chebulagic acid; Combination Index; Cyclooxygenase 2; Dose reduction index; Doxorubicin; HepG2; MDR 1

Indexed keywords

CHEBULAGIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TERMINALIA CHEBULA;

BENZOPYRANS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GLUCOSIDES; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 80051962936     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799087     Document Type: Article

References (60)

1. Gottesmann, M. M.; Fogo, T.; Bates, S. E. Multidrug resistance in cancer-role of ATP dependant transporters. Nat. Rev. Cancer, 2001, 2, 45-48.
2. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398. (Pubitemid 29222564)
3. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets, 2006, 7, 861-879.
4. Ambedkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P glycoprotein from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.
5. Schrenk, D.; Gant, T. W.; Preisegger, K. H.; Silverman, J. A.; Marino, P. A.; Thorgeirsson, S. S. Induction of multidrug resistance gene expression during cholestasis in rats and non human primates. Hepatology, 1993, 17, 854-860. (Pubitemid 23150095)
6. Arino, P. A.; Gottesman, M. M.; Pastan, I. Regulation of multidrug resistance gene in regenerating rat liver. Cell Growth Differ., 1990, 1, 57-62.
7. Koga, H.; Sakisaka, S.; Ohishi, M.; Kawaguchi, T.; Taniguchi, E.; Sasatomi, K.; Harada, M.; Kusaba, T.; Tanaka, M.; Kimura, R.; Nakashima, Y.; Nakashima, O.; Kojiro, M.; Kurohiji, T.; Sata, M. Expression of Cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation. Hepatology, 1999, 29, 688-696. (Pubitemid 29109581)
8. Nagasue, N.; Dhar, D. K.; Makino, Y.; Yoshimura, H.; Nakamura, T. Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis. J. Hepatol., 1995, 22, 197-201.
9. Roy, K. R.; Reddy, G. V.; Maitreyi, L.; Agarwal, S.; Achari, C.; Vali, S.; Reddanna, P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol., 2010, 65, 903-911.
10. Ford, J. M. Experimental reversal of P-glycoprotein mediated multidrug resistance by pharmacological chemosensitizers. Eur. J. Cancer, 1996, 32 A, 991-1001.
11. Zhang, Y. W.; Shi, J.; Li, Y. J.; Wei, L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp., 2009, 57, 435-445.
12. Teodori, E.; Dei, S.; Scapecchi, S.; Gualtieri, F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. II Farmaco, 2002, 57, 385-415. (Pubitemid 34451020)
13. Dragsted, L. O. Natural antioxidants in chemoprevention. Arch. Toxicol. Suppl., 1998, 20, 209-226.
14. Kelloff, G. J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer. Res. 2000, 78, 199-334.
15. Anuchapreeda, S.; Thanarattanakorn, P.; Sittipreechacharn, S.; Tima, S.; Chanarat, P.; Limtrakul, P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch. Pharm. Res., 2006, 29, 866-873. (Pubitemid 44808452)
16. Limtrakul, P.; Anuchapreeda, S.; Buddhasukh, D. Modulation of human multidrug resistance MDR-1 gene by natural curcuminoids, BMC Cancer, 2004, 4, 1-6.
17. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun., 2005, 327, 866-870. (Pubitemid 40092828)
18. Shapiro, A. B.; Ling, V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P glycoprotein. Biochem. Pharmacol., 1997, 53, 587-96. (Pubitemid 27149553)
19. Kitagawa, S.; Nabekura, T.; Kamiyama, S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 2004, 56, 1001-1005. (Pubitemid 39140055)
20. Reddy, D. B.; Reddy, T. C.; Jyotsna, G.; Sharan, S.; Priya, N.; Lakshmipathi, V.; Reddanna, P. Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J. Ethnopharmacol., 2009, 124, 506-512.
21. Reddy, D. B.; Reddanna, P. Chebulagic acid (CA) attenuates LPS-induced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. Biochem. Biophys. Res. Commun., 2009, 381, 112-117.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65, 55-63. (Pubitemid 14203433)
23. Chou, T. C.; Tan, Q. H.; Sirotnak, F. M. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother. Pharmacol., 1993, 31, 259-264. (Pubitemid 23029148)
24. Sambrook, J.; Frotsch, C. F.; Maniatis, T. Molecular Cloning, Plain view; Cold Spring Harbour, 1989.
25. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-254.
26. Bader, P.; Fuchs, J.; Wenderoth, M.; von Schweinitz, D.; Niethammer, D.; Beck, J. F. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin. Anticancer Res., 1998, 18, 3127-3132. (Pubitemid 28388827)
27. Minemura, M.; Tanimura, H.; Tabor, E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int. J. Oncol., 1999, 15, 559-563.
28. Guan, J.; Chen, X. P.; Zhu, H.; Luo, S. F.; Cao, B.; Ding, L. Involvement of extracellular signal-regulated kinase/mitogenactivated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J. Gastroenterol., 2004, 10, 3522-3527. (Pubitemid 39549558)
29. Huang, W. C.; Hung, M. C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc., 2009, 108, 180-194.
30. Gatti, L.; Zunino, F. Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med., 2005, 111, 127-148.
31. Gillet, J. P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta, 2007, 1775, 237-262. (Pubitemid 46899341)
32. Johnstone, R. W.; Ruefli, A. A.; Tainton, K. M.; Smyth, M. J. A role for P-glycoprotein in regulating cell death. Leuk. Lymphoma, 2000, 38, 1-11. (Pubitemid 30224318)
33. Sharom, F. J.; Yu, X.; Lu, P.; Liu, R.; Chu, J. W.; Szabo, K.; Muller, M.; Hose, C. D.; Monks, A.; Varadi, A.; Seprodi, J.; Sarkadi, B. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem. Pharmacol., 1999, 58, 571-586. (Pubitemid 29296877)
34. Sikic, B. I. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology, 1999, 3, 183-187.
35. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol., 2000, 5, 450-458. (Pubitemid 32268882)
36. Roy, K. R.; Nishanth, R. P.; Sreekanth, D.; Reddy, G. V.; Reddanna, P. C-Phycocyanin ameliorates 2-acetylaminofluorene induced oxidative stress and MDR1 expression in the liver of albino mice. Hepatol. Res., 2008, 5, 511-520. (Pubitemid 351593952)
37. Roy, K. R.; Reddy, G. V.; Maitreyi, L.; Agarwal, S.; Achari, C.; Vali, S.; Reddanna, P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol., 2010, 65, 903-911.
38. Patel, V. A.; Dunn, M. J.; Sorokin, A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem., 2002, 277, 38915-38920. (Pubitemid 35154756)
39. Bertagnolli, M. M.; Eagle, C. J.; Zauber, A. G.; Redston, M.; Solomon, S. D.; Kim, K.; Tang, J.; Rosenstein, R. B.; Wittes, J.; Corle, D.; Hess, T. M.; Woloj, G. M.; Boisserie, F.; Anderson, W. F.; Viner, J. L.; Bagheri, D.; Burn, J.; Chung, D. C.; Dewar, T.; Foley, T. R.; HoVman, N.; Macrae, F.; Pruitt, R. E.; Saltzman, J. R.; Salzberg, B.; Sylwestrowicz, T.; Gordon, G. B.; Hawk, E. T. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med, 2006, 355, 873-884. (Pubitemid 44315980)
40. Kawamori, T.; Rao, C. V.; Seibert, K.; Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res, 1998, 58, 409-412. (Pubitemid 28087398)
41. Van Vliet, E. A.; Zibell, G.; Pekcec, A.; Schlichtiger, J.; Edelbroek, P. M.; Holtman, L.; Aronica, E.; Gorter, J. A.; Potschka, H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology, 2010, 58, 404-412.
42. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets., 2006, 7, 861-879.
43. Piasek, A.; Bartoszek, A.; Namiesnik, J. [Phytochemicals that counteract the cardiotoxic side effects of cancer chemotherapy]. Postepy. Hig. Med. Dosw., 2009, 63, 142-158.
44. D'Alessandro, N.; Poma, P.; Montalto, G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J. Gastroenterol., 2007, 13, 2037-2043. (Pubitemid 46795838)
45. Molnar, J.; Engi, H.; Hohmann, J.; Molnar, P.; Deli, J.; Wesolowska, O.; Michalak, K.; Wang, Q. Reversal of Multidrug Resitance by Natural Substances from Plants. Curr. Top. Med. Chem., 2010, 10, 1757-1768.
46. Ugocsai, K.; Varga, A.; Molnar, P.; Antus, S.; Molnar, J. Effects of selected flavonoids and carotenoids on drug accumulation and apoptosis induction in multidrug-resistant colon cancer cells expressing MDR1/LRP. In Vivo, 2005, 19, 433-438. (Pubitemid 40467630)
47. Bhardwaj, R. K.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta, S. K.; Fromm, M. F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 2002, 302, 645-650. (Pubitemid 34787231)
48. Tyagi, A. K.; Singh, R. P.; Agarwal, C.; Chan, D. C. F.; Agarwal, R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest and apoptosis. Clin. Cancer Res., 2002, 8, 3512-3519. (Pubitemid 35340729)
49. Sharma, G.; Tyagi, A. K.; Singh, R. P.; Chan, D. C.; Agarwal, R. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res. Treat., 2004, 85, 1-12. (Pubitemid 38437978)
50. Naus, P. J.; Henson, R.; Bleeker, G.; Wehbe, H.; Meng, F.; Patel, T. Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J. Hepatol., 2007, 46, 222-229. (Pubitemid 44959150)
51. Deeley, R. G.; Westlake, C.; Cole, S. P. C. Transmembrane transport of endo and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev., 2006, 86, 849-899. (Pubitemid 44033384)
52. Plouzek, C. A.; Ciolino, H. P.; Clarke, R.; Yeh, G. C. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur. J. Cancer, 1999, 35, 1541-1545. (Pubitemid 29454653)
53. Eberhart, C. E.; CoVey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107, 1183-1188. (Pubitemid 24294584)
54. Bhushan, A.; Abramson, R.; Chiu, J. F.; Tritton, T. R. Expression of c-fos in human and murine multidrug-resistant cells. Mol. Pharmacol., 1992, 42, 69-74. (Pubitemid 23026129)
55. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M. P.; Bours, V. NF-kB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22, 90-97. (Pubitemid 36152887)
56. Nakanishi, C.; Toi, M. Nuclear factor-KB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer, 2005, 5, 297-309. (Pubitemid 40488635)
57. Romano, M. F.; Avellino, R.; Petrella, A.; Bisogni, R.; Romano, S.; Venuta, S. Rapamycin inhibits doxorubicin-induced NF-KB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer, 2004, 40, 2829-2836. (Pubitemid 39574738)
58. Cusack Jr, J. C.; Liu, R.; Houston, M.; Abendroth, K.; Elliott, P. J.; Adams, J.; Baldwin Jr, A. S. Enhanced chemosensitivity to CPT-11 with protesome inhibitor PS-431: implications for systemic nuclear factor-KB inhibition. Cancer Res., 2001, 61, 3535-3540. (Pubitemid 32694955)
59. Choi, B. H.; Kim, C. G.; Lim, Y.; Shin, S. Y.; Lee, Y. H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett., 2008, 259, 111-118. (Pubitemid 350235095)
60. Gopalakrishnan, A.; Xu, C. J.; Nair, S. S.; Chen, C.; Hebbar, V.; Kong, A. N. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch. Pharm. Res., 2006, 29, 633-644. (Pubitemid 44338461)